Modulation of mesolimbic dopaminergic behaviors by cholecystokinin.
Crawley
J N
JN
Clinical Neuroscience Branch, National Institute of Mental Health, Bethesda, Maryland 20892.
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology*; D002766:Cholecystokinin / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000502:physiology*; D006801:Humans; D008032:Limbic System / Q000502:physiology*; D008636:Mesencephalon / Q000502:physiology*; D012559:Schizophrenia / Q000188:drug therapy; D012844:Sincalide / Q000494:pharmacology
D002766:Cholecystokinin; D012844:Sincalide; D004298:Dopamine